Table 4.
The long-term renal outcome in ANCA GN.
| Parameter | ESKD | No ESKD | p-Value |
|---|---|---|---|
| Intravenous steroid pulse—no. (%) | 6 (100) | 28 (65.1) | |
| Oral GCs—no. (%) | 6 (100) | 43 (100) | |
| PEX—no. (%) | 4 (66.7) | 15 (34.9) | |
| Sessions of PEX (IQR)—no. | 5 (5–7) | 5 (4.25–5) | |
| RTX—no. (%) | 3 (50) | 13 (30.2) | |
| CYC—no. (%) | 3 (50) | 21 (48.8) | |
| RTX/CYC—no. (%) | 0 (0) | 7 (16.3) | |
| Follow-up (IQR)—days | 214 (24.75–1216) | 392 (94–745) | 0.5816 |
| Total fibrosis (IQR)—% | 55 (43.75–65) | 20 (10–40) | 0.0006 |
| Focal IF/TA (IQR)—% | 50 (23.75–65) | 10 (5–30) | 0.0016 |
| Diffuse fibrosis (IQR)—% | 2.5 (0–21.25) | 5 (5–10) | 0.5092 |
Median values and IQR are shown. For group comparisons, the Mann–Whitney U-test was used to determine differences between medians. In addition, non-parametric between-group comparisons were performed with Pearson’s Chi-square test. Abbreviations: ANCA GN—antineutrophil cytoplasmic antibody glomerulonephritis; CYC—cyclophosphamide; GC—glucocorticoids; IF/TA—interstitial fibrosis/tubular atrophy; PEX—plasma exchange; RTX—rituximab.